About This Trial

Intravenously administered mRNA encoding a secreted antibody targeting Claudin 18.2.

Primary Endpoints

  • Safety
  • Antibody expression levels
  • Tumor response

Latest Update

January 2026

Dose escalation ongoing. Therapeutic antibody levels detected in all patients at higher dose levels.